.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Fish and Richardson
Merck
Federal Trade Commission
Harvard Business School
McKesson
Express Scripts
Covington
Julphar

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,050,309

« Back to Dashboard

Which drugs does patent 9,050,309 protect, and when does it expire?


Patent 9,050,309 protects EPANOVA and is included in one NDA.

This patent has twenty-four patent family members in twenty-one countries.

Summary for Patent: 9,050,309

Title:DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
Inventor(s): Maines; Timothy J. (Potomac, MD), Machielse; Bernardus N M (North Potomac, MD), Mehta; Bharat M. (Mendham, NJ), Wisler; Gerald L. (Windermere, FL), Davidson; Michael H. (Highland Park, IL), Wood; Peter Ralph (Cotherstone, GB)
Assignee: Omthera Pharmaceuticals, Inc. (Princeton, NJ) Chrysalis Pharma AG (Sacheln, CH)
Application Number:13/797,557
Patent Claim Types:
see list of patent claims
Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,050,309

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,050,308DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,050,309

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2014128500► Subscribe
Philippines12015502307► Subscribe
Philippines12014501553► Subscribe
New Zealand626699► Subscribe
Mexico2014008309► Subscribe
South Korea20140135695► Subscribe
Japan2015503590► Subscribe
India6125DEN2014► Subscribe
Israel233517► Subscribe
Hong Kong1202073► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Cerilliant
Cantor Fitzgerald
Fish and Richardson
Novartis
Deloitte
Medtronic
Johnson and Johnson
Covington
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot